20.02.2013 Views

Bioidentical Hormones - U.S. Senate Special Committee on Aging

Bioidentical Hormones - U.S. Senate Special Committee on Aging

Bioidentical Hormones - U.S. Senate Special Committee on Aging

SHOW MORE
SHOW LESS

You also want an ePaper? Increase the reach of your titles

YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.

22<br />

adulterati<strong>on</strong> and misbranding provisi<strong>on</strong>s of the FD&C Act do not c<strong>on</strong>tain exempti<strong>on</strong>s for<br />

compounded drugs.<br />

To facilitate enforcement of the approval, adulterati<strong>on</strong>, misbranding, and other FD&C<br />

Act provisi<strong>on</strong>s, C<strong>on</strong>gress has authorized FDA to enter "any . .. establishment" where<br />

drugs are "manufactured, processed, packed, or held" and to inspect such establishments<br />

and "all pertinent equipment, finished and unfinished materials, c<strong>on</strong>tainers, and labeling<br />

therein." Id. §374(a)(1). This authority extends to "all things" in these establishments,<br />

including records relating to prescripti<strong>on</strong> drugs. Id. The statute provides an exempti<strong>on</strong><br />

from records inspecti<strong>on</strong> for pharmacies that comply with local pharmacy law and that<br />

satisfy other criteria. But there is no specific exempti<strong>on</strong> from inspecti<strong>on</strong> for<br />

compounding pharmacies or compounded drugs.<br />

The 1992 Compliance Policy Guide <strong>on</strong> Compounding<br />

FDA has l<strong>on</strong>g interpreted the FD&C Act to apply to compounded drugs, including the<br />

provisi<strong>on</strong>s addressing new drug approval requirements, adulterati<strong>on</strong>, and misbranding.<br />

However, FDA has historically exercised its discreti<strong>on</strong> to exempt from enforcement<br />

pharmacists engaged in traditi<strong>on</strong>al compounding.<br />

In March 1992, resp<strong>on</strong>ding to a significant increase in pharmacy compounding, FDA<br />

issued a compliance policy guide (CPG), secti<strong>on</strong> 7132.16 (later renumbered as 460.200)<br />

to delineate FDA's enforcement policy <strong>on</strong> pharmacy compounding. This CPG relied <strong>on</strong><br />

enforcement discreti<strong>on</strong>, rather than legal exempti<strong>on</strong>s from the FD&C Act's new drug<br />

approval and other requirements, to guide FDA's regulatory approach. After C<strong>on</strong>gress<br />

enacted the Food and Drug Administrati<strong>on</strong> Modernizati<strong>on</strong> Act of 1997 to specifically<br />

address FDA's role in the regulati<strong>on</strong> of pharmacy compounding, the 1992 CPG was<br />

rescinded.<br />

Food and DruE Administrati<strong>on</strong> Modernizati<strong>on</strong> Act of 1997<br />

The Food and Drug Administrati<strong>on</strong> Modernizati<strong>on</strong> Act added secti<strong>on</strong> 503A to the FD&C<br />

Act to clarify the status of pharmacy compounding and compounded drugs under Federal

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!